- Home
- ONL vs FATE Comparison
ONL vs FATE Comparison
Compare ONL & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONL
- FATE
- Stock Information
- Founded
- ONL 2021
- FATE 2007
- Country
- ONL United States
- FATE United States
- Employees
- ONL N/A
- FATE N/A
- Industry
- ONL Real Estate Investment Trusts
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ONL Real Estate
- FATE Health Care
- Exchange
- ONL Nasdaq
- FATE Nasdaq
- Market Cap
- ONL 119.7M
- FATE 130.7M
- IPO Year
- ONL N/A
- FATE 2013
- Fundamental
- Price
- ONL $2.55
- FATE $1.08
- Analyst Decision
- ONL Hold
- FATE Hold
- Analyst Count
- ONL 1
- FATE 7
- Target Price
- ONL N/A
- FATE $3.83
- AVG Volume (30 Days)
- ONL 370.5K
- FATE 1.3M
- Earning Date
- ONL 08-06-2025
- FATE 08-12-2025
- Dividend Yield
- ONL 3.13%
- FATE N/A
- EPS Growth
- ONL N/A
- FATE N/A
- EPS
- ONL N/A
- FATE N/A
- Revenue
- ONL $154,796,000.00
- FATE $13,335,000.00
- Revenue This Year
- ONL N/A
- FATE N/A
- Revenue Next Year
- ONL N/A
- FATE N/A
- P/E Ratio
- ONL N/A
- FATE N/A
- Revenue Growth
- ONL N/A
- FATE 105.85
- 52 Week Low
- ONL $1.46
- FATE $0.66
- 52 Week High
- ONL $4.39
- FATE $4.61
- Technical
- Relative Strength Index (RSI)
- ONL 54.98
- FATE 42.10
- Support Level
- ONL $2.51
- FATE $1.04
- Resistance Level
- ONL $2.72
- FATE $1.35
- Average True Range (ATR)
- ONL 0.12
- FATE 0.08
- MACD
- ONL -0.02
- FATE -0.01
- Stochastic Oscillator
- ONL 37.14
- FATE 12.90
About ONL Orion Office REIT Inc.
Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.